Long-Term Complications After Prostate Cancer Treatment Not Uncommon

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 8, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Nov. 8, 2024 -- Prostate cancer (PCA) treatment is associated with increased rates of complications in the 12 years after treatment, according to a study published online Nov. 7 in JAMA Oncology.

Joseph M. Unger, Ph.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues characterized long-term treatment-related adverse effects and complications in patients treated for PCA versus a general population of older men using data from two large PCA prevention clinical trials linked with Medicare claims records. The analysis included PCA patients treated with prostatectomy or radiotherapy versus an untreated control group.

The study sample included 29,196 participants; 3,946 had PCA, of whom 655 and 1,056 were treated with prostatectomy and radiotherapy, respectively. The researchers found that the 12-year hazard risk for urinary or sexual complications was 7.23 and 2.76 times higher for those with prostatectomy and radiotherapy treatment, respectively, versus untreated participants. The risk for bladder cancer was significantly increased for those treated with radiotherapy (hazard ratio, 2.78), and the risk for radiation-specific outcomes, including radiation cystitis and radiation proctitis, was also significantly increased (hazard ratios, 131.47 and 87.91, respectively). Per 1,000 person-years, the incidence of any one of the 10 treatment-related complications was 124.26, 62.15, and 23.61 for prostatectomy, radiotherapy, and untreated controls, respectively.

"The magnitude of these risks, compared with the relatively small benefit found by randomized clinical trials of PCA screening and treatment, should be explicitly reflected in national cancer screening and treatment guidelines and be integral to shared decision-making with patients before initiation of prostate-specific antigen screening, biopsy, or PCA treatment," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-09 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords